Rx Repeat | Full Measure

Now an important update to our coverage of a new Alzheimer’s drug that drew so much controversy. Aducanumab was approved without one yes vote from the FDA advisory committee. In fact, several members quit over it. And critics say it offers no proof of real benefit but comes with significant health risks. Now, the FDA has given fast track approval to a similar drug made by the same company under what critics see as similar questionable circumstances.

———
Full Measure is a weekly Sunday news program focusing on investigative, original and accountability reporting. The host is Sharyl Attkisson, five-time Emmy Award winner and recipient of the Edward R. Murrow award for investigative reporting. She is backed by a team of award winning journalists.

Each week, we have a cover story that explores untouchable topics in a fearless way including: immigration, terrorism, government waste, national security and whistleblower reports on government and corporate abuse and misdeeds.

Full Measure is broadcast to 43 million households in 79 markets on 162 Sinclair Broadcast Group stations, including ABC, CBS, NBC, FOX, CW, MyTV, Univision and Telemundo affiliates. It also streams live Sunday mornings at 9:30 a.m. ET.

Read more about us at: http://fullmeasure.news/about
Find out where to watch us at: http://fullmeasure.news/about
Like us on Facebook: https://www.facebook.com/FullMeasureNews
Follow us on Twitter: https://twitter.com/FullMeasureNews

This video and all Sinclair Broadcast Group content archives of local news and sports coverage are available for your use. For more information contact us at contentsales@sbgtv.com